Cancer Family
Precursor Lymphoid Neoplasm
CI-CAN-00000327Explore in graph →
Hematologic567 active trials12 approved drugs212 evidence items
- NCIt
- C7055
Loading cancer entity…
Cancer Family
CI-CAN-00000327Explore in graph →
Clinical trials
2,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (286)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05501899 | Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 20 | Children's Hospital of Orange CountyOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06393335 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research | unknown | Early Phase 1 | 36 | The Children's Hospital of Zhejiang University School of MedicineOTHER |
| 1 |
| May 1, 2024 |
| clinicaltrials |
| NCT04173988 | Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 6 | Children's Hospital of Fudan UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06277011 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05747157 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Nov 21, 2023 | clinicaltrials |
| NCT05739227 | Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies | unknown | Early Phase 1 | 12 | Xuzhou Medical UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05651191 | To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL | unknown | Early Phase 1 | 9 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT04626726 | Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04626765 | CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04532268 | A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL | unknown | Early Phase 1 | 72 | Zhejiang UniversityOTHER | 1 | Aug 31, 2020 | clinicaltrials |
| NCT04129099 | A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | unknown | Early Phase 1 | 18 | Hebei Yanda Ludaopei HospitalOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT04226989 | A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy | unknown | Early Phase 1 | 72 | He HuangOTHER | 1 | Feb 21, 2020 | clinicaltrials |
| NCT04264039 | Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies | unknown | Early Phase 1 | 30 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT04191941 | Treatment of Hematological Malignancy With Novel CAR-T Cells. | unknown | Early Phase 1 | 9 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04184414 | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04166838 | The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) | unknown | Early Phase 1 | 20 | Shanghai Longyao Biotechnology Inc., Ltd.OTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT03825731 | A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | unknown | Early Phase 1 | 20 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Jan 31, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Aug 21, 2024source: clinicaltrials